{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:24:28Z","timestamp":1774441468563,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-026-02203-8","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:26:36Z","timestamp":1771241196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting overall survival after initial chemotherapy for diffuse large B-cell lymphoma using CT nomogram analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Manxin","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaona","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"1","key":"2203_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74\u201387.","journal-title":"Pathology"},{"issue":"3","key":"2203_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/0366-6999.150111","volume":"128","author":"YR Ren","year":"2015","unstructured":"Ren YR, Jin YD, Zhang ZH, et al. Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis. Chin Med J (Engl). 2015;128(3):378\u201383.","journal-title":"Chin Med J (Engl)"},{"key":"2203_CR3","doi-asserted-by":"crossref","unstructured":"Feugier P, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the groupe d\u2019Etude des lymphomes de l\u2019adulte. J Clin Oncol. 2005;4117\u201326.","DOI":"10.1200\/JCO.2005.09.131"},{"issue":"16","key":"2203_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u201308.","journal-title":"Blood"},{"issue":"23","key":"2203_CR5","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135(23):2041\u201348.","journal-title":"Blood"},{"key":"2203_CR6","doi-asserted-by":"crossref","unstructured":"International non-Hodgkin\u2019s lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"issue":"1","key":"2203_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-019-0761-2","volume":"12","author":"W Li","year":"2019","unstructured":"Li W, Gupta SK, Han W, Kundson RA, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73.","journal-title":"J Hematol Oncol"},{"issue":"20","key":"2203_CR8","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL rituximab-CHOP consortium program. Blood. 2013;121(20):4021\u201331.","journal-title":"Blood"},{"issue":"22","key":"2203_CR9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual M, Mena-Varas M, et al. PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133(22):2401\u201312.","journal-title":"Blood"},{"key":"2203_CR10","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines insights: B-Cell lymphomas 3. 2025. J Natl Compr Canc Netw. 2025;23(10):e250048."},{"issue":"1","key":"2203_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0000000000001880","volume":"43","author":"L Baratto","year":"2018","unstructured":"Baratto L, Davidzon GA, Moghbel M, et al. Comparison between different PET and CT-Based imaging interpretation criteria at Interim imaging in patients with diffuse large B-Cell Lymphoma. Clin Nucl Med. 2018;43(1):1\u20138.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2203_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.6004\/jnccn.2015.0025","volume":"13","author":"HJ Adams","year":"2015","unstructured":"Adams HJ, de Klerk JM, Fijnheer R, et al. CT-based versus FDG-PET\/CT-based NCCN international prognostic index risk stratification in DLBCL. J Natl Compr Canc Netw. 2015;13(2):171\u201376.","journal-title":"J Natl Compr Canc Netw"},{"key":"2203_CR13","doi-asserted-by":"crossref","unstructured":"Duarte S, Roque A, Saraiva T, et al. Interim FDG18-PET SUVmax variation adds prognostic value to Deauville 5-point scale in the identification of patients with ultra-high-risk diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2023;23(2):e107\u201316.","DOI":"10.1016\/j.clml.2022.11.009"},{"key":"2203_CR14","doi-asserted-by":"publisher","first-page":"153535082412579","DOI":"10.1177\/15353508241257924","volume":"23","author":"SB Singh","year":"2024","unstructured":"Singh SB, Bhandari S, Siwakoti S, et al. PET\/CT in the evaluation of CAR-T cell immunotherapy in hematological malignancies. Mol Imag. 2024;23:15353508241257924.","journal-title":"Mol Imag"},{"key":"2203_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12880-022-00768-8","volume":"22","author":"C Yu","year":"2022","unstructured":"Yu C, Li T, Yang X, et al. Contrast-enhanced CT-based radiomics model for differentiating risk subgroups of thymic epithelial tumors. BMC Med Imag. 2022;22:37.","journal-title":"BMC Med Imag"},{"issue":"1","key":"2203_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1148\/radiol.2021200928","volume":"299","author":"M Ligero","year":"2021","unstructured":"Ligero M, Garcia-Ruiz A, Viaplana C, et al. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors. Radiology. 2021;299(1):109\u201319.","journal-title":"Radiology"},{"issue":"1","key":"2203_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semradonc.2022.10.009","volume":"33","author":"NS Moore","year":"2023","unstructured":"Moore NS, McWilliam A, Aneja S. Bladder Cancer radiation oncology of the future: prognostic modelling, radiomics, and treatment planning with artificial intelligence. Semin Radiat Oncol. 2023;33(1):70\u201375.","journal-title":"Semin Radiat Oncol"},{"issue":"13","key":"2203_CR18","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s00259-023-06405-y","volume":"50","author":"C Jiang","year":"2023","unstructured":"Jiang C, Qian C, Jiang Z, et al. Robust deep learning-based PET prognostic imaging biomarker for DLBCL patients: a multicenter study. Eur J Nucl Med Mol Imag. 2023;50(13):3949\u201360.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"2203_CR19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s00330-016-4470-8","volume":"27","author":"B Ganeshan","year":"2017","unstructured":"Ganeshan B, Miles KA, Babikir S, et al. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin\u2019s and aggressive non-hodgkin\u2019s lymphomas. Eur Radiol. 2017;27(3):1012\u201320.","journal-title":"Eur Radiol"},{"issue":"11","key":"2203_CR20","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1007\/s00330-020-06927-1","volume":"30","author":"H Wang","year":"2020","unstructured":"Wang H, Zhou Y, Li L, et al. Current status and quality of radiomics studies in lymphoma: a systematic review. Eur Radiol. 2020;30(11):6228\u201340.","journal-title":"Eur Radiol"},{"issue":"4","key":"2203_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11307-022-01703-7","volume":"24","author":"H Jiang","year":"2022","unstructured":"Jiang H, Li A, Ji Z, et al. Role of radiomics-based baseline PET\/CT imaging in lymphoma: diagnosis, prognosis, and response assessment. Mol Imag Biol. 2022;24(4):537\u201349.","journal-title":"Mol Imag Biol"},{"key":"2203_CR22","doi-asserted-by":"crossref","unstructured":"Senjo H, Hirata K, Izumiyama K, et al. High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Adv. 2020 26;4(10):2286\u201396.","DOI":"10.1182\/bloodadvances.2020001816"},{"key":"2203_CR23","doi-asserted-by":"crossref","unstructured":"Durot C, Durot E, Mul\u00e9 S, et al. Pretreatment CT texture parameters as predictive biomarkers of progression-free survival in follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Diagn (Basel). 2023 30; 13(13):2237.","DOI":"10.3390\/diagnostics13132237"},{"issue":"10","key":"2203_CR24","doi-asserted-by":"publisher","first-page":"101188","DOI":"10.1016\/j.tranon.2021.101188","volume":"14","author":"R Santiago","year":"2021","unstructured":"Santiago R, Ortiz Jimenez J, Forghani R, et al. CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell lymphoma. Transl Oncol. 2021;14(10):101188.","journal-title":"Transl Oncol"},{"key":"2203_CR25","doi-asserted-by":"crossref","unstructured":"Jing F, Liu Y, Zhao X, et al. Baseline (18)F-FDG PET\/CT radiomics for prognosis prediction in diffuse large B cell lymphoma. EJNMMI Res. 2023 26;13(1):92.","DOI":"10.1186\/s13550-023-01047-5"},{"issue":"4","key":"2203_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.7150\/ijbs.67892","volume":"18","author":"XJ Liang","year":"2022","unstructured":"Liang XJ, Song XY, Wu JL, et al. Advances in multi-omics study of prognostic biomarkers of diffuse large B-Cell Lymphoma. Int J Biol Sci. 2022;18(4):1313\u201327.","journal-title":"Int J Biol Sci"},{"key":"2203_CR27","doi-asserted-by":"crossref","unstructured":"Zhao J, Zhang Y, Wang W, et al. Clinical characteristics, outcomes, and risk factors for patients with diffuse large B-Cell lymphoma and development of nomogram to identify high-risk patients. J Oncol 2022;2022:8395246.","DOI":"10.1155\/2022\/8395246"},{"issue":"6","key":"2203_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00277-023-05179-5","volume":"102","author":"J Yoon","year":"2023","unstructured":"Yoon J, Kim KH, Kim JS, et al. Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years\u2019 real-world experience in a single institute. Ann Hematol. 2023;102(6):1467\u201376.","journal-title":"Ann Hematol"},{"issue":"2","key":"2203_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21037\/atm-22-6023","volume":"11","author":"Y Chen","year":"2023","unstructured":"Chen Y, Xu J, Meng J, et al. Establishment and evaluation of a nomogram for predicting the survival outcomes of patients with diffuse large B-cell lymphoma based on International prognostic Index scores and clinical indicators. Ann Transl Med. 2023;11(2):71.","journal-title":"Ann Transl Med"},{"key":"2203_CR30","doi-asserted-by":"publisher","first-page":"1153790","DOI":"10.3389\/fimmu.2023.1153790","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, Wu Y, Liu J, et al. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: the central and Western China AIDS lymphoma league 001 study (CALL-001 study). Front Immunol. 2023;14:1153790.","journal-title":"Front Immunol"},{"issue":"10","key":"2203_CR31","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2967\/jnumed.122.265244","volume":"64","author":"S Zhao","year":"2023","unstructured":"Zhao S, Wang J, Jin C, et al. Stacking ensemble learning-based [18F]FDG PET radiomics for outcome prediction in diffuse large B-cell lymphoma. J Nucl Med. 2023;64(10):1603\u201309.","journal-title":"J Nucl Med"},{"issue":"4","key":"2203_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.diii.2022.11.003","volume":"104","author":"J Greffier","year":"2023","unstructured":"Greffier J, Villani N, Defez D, et al. Spectral CT imaging: technical principles of dual-energy CT and multi-energy photon-counting CT. Diagn Interv Imag. 2023;104(4):167\u201377.","journal-title":"Diagn Interv Imag"},{"key":"2203_CR33","doi-asserted-by":"crossref","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on malignant lymphomas imaging working group. J Clin Oncol. 2014: 3048\u201358, 32.","DOI":"10.1200\/JCO.2013.53.5229"},{"issue":"7","key":"2203_CR34","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/bloodadvances.2023011425","volume":"8","author":"Y Wang","year":"2024","unstructured":"Wang Y, Shi Q, Shi ZY, et al. Biological signatures of the International prognostic Index in diffuse large B-cell lymphoma. Blood Adv. 2024;8(7):1587\u201399.","journal-title":"Blood Adv"},{"key":"2203_CR35","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135:2041\u201348.","journal-title":"Blood"},{"key":"2203_CR36","doi-asserted-by":"crossref","unstructured":"Yu CH, Zhang RP, Yang XT, et al. Dual-energy CT perfusion imaging for differentiating invasive thymomas, thymic carcinomas, and lymphomas in adults. Clin Radiol. 2022;77:e417\u201324.","DOI":"10.1016\/j.crad.2022.02.012"},{"issue":"7","key":"2203_CR37","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1177\/02841851221095237","volume":"64","author":"D Geng","year":"2023","unstructured":"Geng D, Chen X, Zhao XG, et al. Laryngeal and hypopharyngeal squamous cell carcinoma: association between quantitative parameters derived from dual-energy CT and histopathological prognostic factors. Acta Radiol. 2023;64(7):2268\u201376.","journal-title":"Acta Radiol"},{"issue":"1","key":"2203_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40644-023-00549-8","volume":"23","author":"V Koch","year":"2023","unstructured":"Koch V, Weitzer N, Dos Santos DP, et al. Multiparametric detection and outcome prediction of pancreatic cancer involving dual-energy CT, diffusion-weighted MRI, and radiomics. Cancer Imag. 2023;23(1):38.","journal-title":"Cancer Imag"},{"key":"2203_CR39","doi-asserted-by":"crossref","unstructured":"Mahmoudi S, Gruenewald LD, Eichler K, et al. Advanced biomedical imaging for accurate discrimination and prognostication of mediastinal masses. Eur J Clin Invest. 2023;53(12):e14075.","DOI":"10.1111\/eci.14075"},{"issue":"5","key":"2203_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679\u201390.","journal-title":"Nat Med"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-026-02203-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-026-02203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:28:54Z","timestamp":1774430934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-026-02203-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2203"],"URL":"https:\/\/doi.org\/10.1186\/s12880-026-02203-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}